LGBTQ+ Cancer Survivors: Lessons Learned and the Road Ahead
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.
Progress Against Cancer
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.
Transgender and gender nonconforming people are most likely to have continuing conditions, regardless of age, race and ethnicity, smoking history, and socioeconomic status, according to A study. Of people who have survived cancer, those...
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) plus the chemotherapies carboplatin and paclitaxel, followed by pembrolizumab...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients with leukemia. The U.S. Food and Drug Administration (FDA) has approved blinatumomab (Blincyto) for use...
Lung cancer screening linked to lower mortality in real-world data, and researchers study unusual cancer patterns after COVID-19 infection.
The immunotherapy durvalumab may be used with chemotherapy to treat certain endometrial cancers. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) with chemotherapy, followed by durvalumab alone, for advanced or recurrent...
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib (Augtyro) for...
Kinase inhibitor trametinib may spare patients from intensive treatments, such as stem cell transplant, for An aggressive form of blood cancer in Small Children. Researchers say they have found a new way to treat...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for adults and children 2 years and...
The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration (FDA) has approved imetelstat (Rytelo) for patients with low-risk or intermediate-1 risk myelodysplastic syndromes (MDS)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More